360 related articles for article (PubMed ID: 14515717)
21. The role of endotoxin and the innate immune response in the pathophysiology of acute graft versus host disease.
Cooke KR; Olkiewicz K; Erickson N; Ferrara JL
J Endotoxin Res; 2002; 8(6):441-8. PubMed ID: 12697087
[TBL] [Abstract][Full Text] [Related]
22. Effect of FK506 on donor T-cell functions that are responsible for graft-versus-host disease and graft-versus-leukemia effect.
Imado T; Iwasaki T; Kuroiwa T; Sano H; Hara H
Transplantation; 2004 Feb; 77(3):391-8. PubMed ID: 14966413
[TBL] [Abstract][Full Text] [Related]
23. Induction of graft-versus-leukemia (GVL) effect without graft-versus-host disease (GVHD) by pretransplant donor treatment with immunomodulators.
Morecki S; Yacovlev E; Gelfand Y; Shabat Y; Slavin S
Biol Blood Marrow Transplant; 2009 Apr; 15(4):406-15. PubMed ID: 19285627
[TBL] [Abstract][Full Text] [Related]
24. [Effect of Ly49A transfected mouse spleen cells on graft versus host disease and graft versus leukemia after haploidentical allogeneic bone marrow transplantation in mice].
Li Y; Guo K; Chen Y; Song Z; Li J; Deng L
Zhonghua Xue Ye Xue Za Zhi; 2002 Aug; 23(8):411-4. PubMed ID: 12411044
[TBL] [Abstract][Full Text] [Related]
25. Graft-vs.-host and graft-vs.-leukemia reactions after delayed infusions of donor T-subsets.
Johnson BD; Becker EE; Truitt RL
Biol Blood Marrow Transplant; 1999; 5(3):123-32. PubMed ID: 10392958
[TBL] [Abstract][Full Text] [Related]
26. The effect of human IL-2-activated natural killer and T cells on graft-versus-host disease and graft-versus-leukemia in SCID mice bearing human leukemic cells.
Xun CQ; Thompson JS; Jennings CD; Brown SA
Transplantation; 1995 Oct; 60(8):821-7. PubMed ID: 7482742
[TBL] [Abstract][Full Text] [Related]
27. Tetrameric HLA class I-minor histocompatibility antigen peptide complexes demonstrate minor histocompatibility antigen-specific cytotoxic T lymphocytes in patients with graft-versus-host disease.
Mutis T; Gillespie G; Schrama E; Falkenburg JH; Moss P; Goulmy E
Nat Med; 1999 Jul; 5(7):839-42. PubMed ID: 10395333
[TBL] [Abstract][Full Text] [Related]
28. Th2 and Tc2 cells in the regulation of GVHD, GVL, and graft rejection: considerations for the allogeneic transplantation therapy of leukemia and lymphoma.
Fowler DH; Gress RE
Leuk Lymphoma; 2000 Jul; 38(3-4):221-34. PubMed ID: 10830730
[TBL] [Abstract][Full Text] [Related]
29. In vitro separation of host specific graft-versus-host and graft-versus-leukemia cytotoxic T cell activities.
van Lochem E; de Gast B; Goulmy E
Bone Marrow Transplant; 1992 Aug; 10(2):181-3. PubMed ID: 1525608
[TBL] [Abstract][Full Text] [Related]
30. The expanding horizon of immunotherapy in the treatment of malignant disorders: allogeneic hematopoietic stem cell transplantation and beyond.
Tsirigotis P; Shimoni A; Nagler A
Ann Med; 2014 Sep; 46(6):384-96. PubMed ID: 24888385
[TBL] [Abstract][Full Text] [Related]
31. Alloreactivity and the predictive value of anti-recipient specific interleukin 2 producing helper T lymphocyte precursor frequencies for alloreactivity after bone marrow transplantation.
Russell CA
Dan Med Bull; 2002 May; 49(2):89-108. PubMed ID: 12064093
[TBL] [Abstract][Full Text] [Related]
32. Pretransplant tumor antigen-specific immunization of allogeneic bone marrow transplant donors enhances graft-versus-tumor activity without exacerbation of graft-versus-host disease.
Anderson LD; Mori S; Mann S; Savary CA; Mullen CA
Cancer Res; 2000 Oct; 60(20):5797-802. PubMed ID: 11059776
[TBL] [Abstract][Full Text] [Related]
33. CD8+ cytotoxic T cell repertoire implicated in grafts-versus-leukemia effect in a murine bone marrow transplantation model.
de La Selle V; Riché N; Dorothé G; Bruley-Rosset M
Bone Marrow Transplant; 1999 May; 23(9):951-8. PubMed ID: 10338053
[TBL] [Abstract][Full Text] [Related]
34. Donor T cells administered over HLA class II barriers mediate antitumor immunity without broad off-target toxicity in a NOD/scid mouse model of acute leukemia.
Stevanović S; Nijmeijer BA; van Schie ML; Salvatori DC; Maas S; Griffioen M; Falkenburg JH
Biol Blood Marrow Transplant; 2013 Jun; 19(6):867-75. PubMed ID: 23500532
[TBL] [Abstract][Full Text] [Related]
35. Donor lymphocyte infusions combined with systemic PUVA/bexarotene as an effective bimodal immunologic approach in a patient with relapsed cutaneous T cell lymphoma after allogeneic stem cell transplantation.
Schlaak M; Kurschat P; Shimabukuro-Vornhagen A; Scheid C; Chemnitz J; Stadler R; von Bergwelt-Baildon M; Theurich S
Transpl Immunol; 2011 Sep; 25(2-3):163-6. PubMed ID: 21745569
[TBL] [Abstract][Full Text] [Related]
36. Strategies for Enhancing and Preserving Anti-leukemia Effects Without Aggravating Graft-Versus-Host Disease.
Chang YJ; Zhao XY; Huang XJ
Front Immunol; 2018; 9():3041. PubMed ID: 30619371
[TBL] [Abstract][Full Text] [Related]
37. Selective graft-versus-leukemia depends on magnitude and diversity of the alloreactive T cell response.
van Bergen CA; van Luxemburg-Heijs SA; de Wreede LC; Eefting M; von dem Borne PA; van Balen P; Heemskerk MH; Mulder A; Claas FH; Navarrete MA; Honders WM; Rutten CE; Veelken H; Jedema I; Halkes CJ; Griffioen M; Falkenburg JH
J Clin Invest; 2017 Feb; 127(2):517-529. PubMed ID: 28067665
[TBL] [Abstract][Full Text] [Related]
38. [Role of NK cells in allogeneic hematopoietic stem cell transplantation--review].
Li XH; Gao CJ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2006 Aug; 14(4):845-8. PubMed ID: 16928336
[TBL] [Abstract][Full Text] [Related]
39. Role of alloreactive KIR2DS1(+) NK cells in haploidentical hematopoietic stem cell transplantation.
Marcenaro E; Carlomagno S; Pesce S; Della Chiesa M; Moretta A; Sivori S
J Leukoc Biol; 2011 Oct; 90(4):661-7. PubMed ID: 21791599
[TBL] [Abstract][Full Text] [Related]
40. Minor histocompatibility antigens in human stem cell transplantation.
Falkenburg JH; van de Corput L; Marijt EW; Willemze R
Exp Hematol; 2003 Sep; 31(9):743-51. PubMed ID: 12962719
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
